LumaCyte: Paul Meister, Peter Buzy
LumaCyte, a developer of platforms for label-free, single-cell analytics, has appointed Paul Meister and Peter Buzy to its board of directors in connection with the completion of a Series A financing round for an undisclosed amount.
Meister is a partner in investment and advisory firm Novalis LifeSciences and a founder of private investment company Liberty Lane Partners. He previously was at Thermo Fisher Scientific and Fisher Scientific for more than 16 years, ultimately becoming chairman of the board. He also currently serves on the board of Ori Biotech, Quanterix, and other private life science companies, and is chairman of the board at Amneal Pharmaceuticals and Arbor Biotechnologies.
Buzy most recently served as chairman of Catalent's gene therapy division after joining the organization in 2019 as president of the gene therapy division. He was also president and CEO of Paragon Bioservices prior to its acquisition by Catalent.